The purpose of this study is to review recent evidence for the role of the cytosolic fatty acid binding proteins (FABPs) as central regulators of whole-body metabolic control.
INTRODUCTION
The human intracellular fatty acid binding proteins (FABPs) are expressed in most of the major tissues, likely reflecting their critical biological roles. They are small ($15 kDa) cytosolic proteins that bind unesterified long-chain fatty acids, and other ligands, with nanomolar affinity. Through their control of fatty acid transport, metabolism and storage, FABPs are proposed to be central regulators of lipid metabolism, inflammation and energy homeostasis [1] . It is intriguing that there are at least eight separate human isoforms that, although possessing only moderate sequence homology, have similar protein structures and ligand-binding properties [1] . In this review, we have excluded discussions of FABPs as potential biomarkers of tissue damage, focusing instead on interesting recent data that broaden our understanding of these proteins, while also posing new questions regarding their role in health and metabolic diseases.
FATTY ACID BINDING PROTEIN 1 (LIVER FATTY ACID BINDING PROTEIN)
FABP1, first isolated from liver tissue, plays a central role in the hepatic b-oxidation of unesterified fatty acids, both through fatty acid trafficking and the regulation of gene expression through interactions with PPARa [1] . Recent reports continue to implicate FABP1 downregulation in steatotic livers and nonalcoholic fatty liver disease (NAFLD) [ ] demonstrates that, in mice, FABP1 is required to maintain intracellular lipid droplets in hepatic stellate cells (HSCs). Typically quiescent, HSCs store vitamin A in lipid droplets; however, downregulation of FABP1 resulted in their activation, proliferation, loss of lipid droplets and HSC secretion of collagen and extracellular matrix proteins, leading to hepatic fibrogenesis.
In the intestine, FABP1 has a role distinct from that of FABP2 (intestinal FABP, see below 
FATTY ACID BINDING PROTEIN 2 (INTESTINAL FATTY ACID BINDING PROTEIN)
Intestinal enterocytes express FABP2, commonly described as intestinal FABP, in addition to FABP1. Recent work shows that FABP2-/-knockout mice lose weight in response to high fat feeding, decreased incorporation of fatty acids into triacylglycerols relative to phospholipids and preferentially utilized carbohydrates as an energy source [7 && ]. Considering the important role of the intestine in terms of nutrient uptake, it is rather surprising that more studies have not focussed on the functions of FABPs (including FABP6) in this tissue.
FATTY ACID BINDING PROTEIN 3 (HEART/ MUSCLE FATTY ACID BINDING PROTEIN)
In addition to its expression in cardiac and skeletal muscle tissues, where its primary role is the trafficking of fatty acids, FABP3 is also expressed in a wide range of other tissues, albeit at significantly lower levels; these include testes, brain, kidney, lung, adrenal gland and lymphocytes [1] . It is increasingly recognized that skeletal muscle does not exist as an isolated functional unit but can contribute to paracrine and endocrine signalling, regulating energy demands through the secretion of key signalling molecules (myokines). FABP3 has been proposed as one such myokine, with exercise-associated increases observed in human skeletal muscle [13] , as well as increased secretion from rat gastrocnemius muscle [14 && ]. Recent work has highlighted a distinct role for FABP3 in apoptosis. For example, knockdown of FABP3 expression in vitro is associated with reduced proliferation and increased apoptosis in the P19 cardiac cell line [15] , an effect that can be prevented through the use of the natural antioxidant a-lipoic acid [16] . This implies that FABP3 may have a role in protection against oxidative stress. Studies in the model species zebrafish have replicated such findings, demonstrating that cardiac muscle specific knockdown of FABP3 resulted in mitochondrial dysfunction, increased reactive oxygen species generation and increased apoptosis [17] . Furthermore, cardiac organogenesis was severely impaired when FABP3 functioning was disrupted during the early stages of development. The exact mechanism for these effects is still not clear, although the Wnt, RAR and mTORC2 signalling pathways have been implicated [17] [18] [19] .
FATTY ACID BINDING PROTEIN 4 (ADIPOCYTE FATTY ACID BINDING PROTEIN)
The main cells expressing FABP4 are differentiated adipocytes and macrophages [1] , with substantial KEY POINTS FABP1, FABP2 and FABP4 are implicated in steatosis, NAFLD, atherosclerosis, insulin resistance and the metabolic syndrome. FABP1 and FABP2 have different roles in the intestine, with divergent whole-body downstream effects on energy metabolism and obesity. FABP1, FABP4 and FABP5 are indirect regulators of gene expression through interactions with PPARa and PPARg.
FABP4 is involved in the metabolic crosstalk of Kupffer cells with hepatocytes in the liver and macrophages with adipocytes in the adipose tissue. crosstalk between these cell types occurring in adipose tissue [20 && ]. In addition to its traditional role in trafficking of unesterified fatty acids within cells, for example to and from PPARg and hormone-sensitive lipase (HSL) [1, 21] , FABP4 is now recognized as an adipokine secreted from adipocytes and macrophages [21] . Increasing evidence exists for a link between lipid metabolism and inflammation, and FABP4 may mediate these effects, thus impacting on disease conditions such as metabolic syndrome, insulin resistance, NAFLD and atherosclerosis [21, 22, 23 && ,24-26,27 & ,28]. For example, hepatic Kupffer cells are intimately involved in NAFLD pathogenesis and recent data have demonstrated that FABP4 is increased in Kupffer cells of NAFLD patients and may be linked to increased proinflammatory cytokines and liver inflammation [5 & ]. Further support for the role of FABP4 as an adipokine has been provided by in-vitro studies demonstrating that interaction between adipocytes and macrophages increases the secretion of FABP4 into culture medium [27 & ], and serum levels of FABP4 have been directly correlated with levels of adiposity [29] , metabolic syndrome, atherosclerosis [21] and the long-term prognosis of cardiovascular mortality [23 && ]. The expression of FABP4 has also been linked to the rupture of atherosclerotic plaques [30] , production of proinflammatory leukotriene C 4 [31] , IL-6/VEGF expression [26] , angiogenesis in endothelial cells [32] and increased adipogenic differentiation of primary osteoblasts [33] .
Paradoxically, pharmacological inhibition of fatty acid binding to FABP4 reversed NAFLD [5 & ], while decreased FABP4 expression in adipocytes increased lipolysis [27 & ]. These studies reinforce previous studies showing that FABP4 has an important role in fatty acid storage, in the form of triacylglycerol. However, as pointed out by Ohira et al. [27 & ], an increase in lipolysis from adipocytes may contribute to the development of insulin resistance. Together, these suggest that reduced functionality of FABP4 mediated by short-chain fatty acids, statins, peptides, knockdown strategies or pharmacological compounds [5 FATTY ACID BINDING PROTEIN 5 (EPITHELIAL FATTY ACID BINDING PROTEIN, KERATINOCYTE FATTY ACID BINDING PROTEIN) FABP5 has been found at detectable levels in adipocytes, macrophages, endothelial cells, lung epithelium, neural tissues and breast tumour [1, 37, 38] . The role of FABPs in regulating cell proliferation is also seen with FABP5, wherein levels are upregulated in breast tumours, promoting proliferation and metastatis in cultured cells, most likely through interactions with PPARd [37] . A link between FABP5 and the immune system has also been recently demonstrated in a study investigating the response of lung epithelial cells to infection by influenza virus. Interestingly, a biphasic expression of FABP5 was observed in this study, with an initial downregulation as part of immune response initiation, followed by recovery of expression levels to aid attenuation of the inflammatory response, possibly in conjunction with increased expression of PPARg [39 & ]. A specific inhibitor of FABP5, namely AM404, was used to show that FABP5 enhances the action of N-acylethanolamine, a PPARa agonist, by increasing its uptake and nuclear translocation in Hela cells [38] . Thus, several studies have shown that FABP5 interacts with the PPAR class of nuclear receptors and we speculate that these interactions are cell and tissue-dependent, although probably also driven by substrate supply and the metabolic requirements of the specific cells.
FATTY ACID BINDING PROTEIN 7 (BRAIN FATTY ACID BINDING PROTEIN)
The brain expresses three FABP isoforms in a dynamic spatio-temporal fashion, namely FABP3, FABP5 and FABP7 [1] . Recent work with FABP5 and FABP7 knockout mice has demonstrated that both proteins are required for proliferation of neural stem cells, but negatively affect the survival of immature neurons in the postnatal hippocampus [40] . Consistent with these observations, aberrant expression of FABP7 is detected in human glioma biopsies and is associated with invasion and progression of this malignancy [41, 42] . FABP7 is almost exclusively expressed in glioblastoma-derived neurospheres, which are believed to contain the stem-like cells responsible for tumour recurrence, with downregulation of FABP7 expression resulting in reduced neurosphere migration [41] . Related to this, Liu et al. [42] demonstrated that the Pax6 transcription factor, which is also expressed in brain tumour tissue and tumour neurospheres, is an inducer of FABP7 expression; a reduction of Pax6 expression reduced FABP7 levels in malignant glioma cells.
Separately, aberrant expression of FABP7 has been associated with poor prognosis of triple-negative breast cancer [43] . Interestingly, this association is not through FABP7 expression directly, but rather through the subcellular localization of this protein.
A tissue microarray screening of almost 1500 invasive breast cancers [44] revealed heterogeneity in subcellular localization, with cytoplasmic versus nuclear FABP7 having different prognostic implications dependent on breast cancer type. FABP7 expression exclusively in the nucleus showed a better prognosis than tumours with cytosol-only expression, although the mechanistic rationale for this finding is unclear [44] .
It has recently been demonstrated that FABP7 translation is regulated in a circadian fashion through alterations in poly(A) tail processing [45] . This finding implies that subcellular trafficking of fatty acids, as mediated by FABP7, may be affected by circadian and/or sleep cycles [45] , a topic that is of broad interest as disruption of these processes has been linked to increased occurrence of metabolic disease.
CLINICALLY RELEVANT POLYMORPHISMS WITHIN THE FATTY ACID BINDING PROTEIN FAMILY
Given the important roles of FABPs, it is perhaps not surprising that polymorphisms in FABP genes are associated with the increased incidence of diseases within the obesity-metabolic syndrome-insulin resistance-type 2 diabetes spectrum ( Table 1) . As such, it is important to view these variants in light of their potential role in the spectrum of these disorders, rather than just with a single disease phenotype. Equally, the identification of a FABP2 polymorphism linked to cancer (Table 1) can also be understood through the role of several FABPs in this disease spectrum, as described above.
Several studies show that FABP genetic variants may affect an individual's response to lifestyle interventions designed to reduce the risk of obesityrelated diseases. For example, obese individuals with the FABP2 (Ala54Thr) variant responded better to hypocaloric diets than controls (Ala54Ala) in terms of anthropometric (e.g. BMI, waist circumference) and biochemical (e.g. HOMA-IR, total cholesterol) factors [46, 47] . In addition, the exact fat composition appears to be critical for an optimal response, as improved anthropometric changes were replicated in Ala54Thr individuals fed a hypocaloric diet that was high in monounsaturated fats, although under this paradigm biochemical factors responded significantly poorer than controls [48] . In a similar vein, Pishva et al. [49] demonstrated that individuals with the Ala54Thr variant showed an improved response to eicosapentaenoic acid (EPA), with higher plasma levels of v-3 and v-6 fatty acids [49] . These studies suggest that FABP variants do affect the response to lifestyle management, although this is highly dependent on the fatty acid composition within the diet and hence may be difficult to reproduce in the general population.
Zhang et al. [50 && ] have recently shown that the promoter methylation status of FABP3 is significantly altered in individuals with metabolic syndrome, suggesting that epigenetic regulation may also play an important role in FABP physiology. The role of epigenetic modifications on gene functioning is a rapidly emerging field and one that promises to fill in many gaps in the understanding of an individual's predisposition to disease and will complement studies on the impact genetic variation on disease aetiology.
CONCLUSION
The historically held view that FABPs are of minimal interest, acting merely as biologically silent traffickers of fatty acids, is dispelled by the above studies. It is becoming increasingly clear that the FABPs are important constituents of cellular and systemic metabolic networks, with functions in most of the major tissues that impact a wide range of disease causes. Such roles will be further elucidated through the use of untargeted studies focussed on, amongst others, the transcriptome, proteome and metabolome, technologies that have been poorly applied to FABP biology to date. 
